Amiloidózis: vizsgálatok itt: Írország
6 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleCLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
- Where
- Ballinasloe, Dublin, Letterkenny
- Életkor
- 18 év and over
- People
- 1280 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07207811 - 3. fázisTaking peopleTRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Dublin 7, Dublin 8
- Életkor
- 18 év to 85 év
- People
- 1750 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00 - 3. fázisTaking peopleTRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- Where
- Dublin 24
- Életkor
- 18 év to 85 év
- People
- 125 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00 - 3. fázisNot yet taking people in ÍrországAn Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
- Where
- Dublin
- People
- 1180 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00 - 3. fázisNot yet taking people in ÍrországTo Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
- Where
- Dublin 24, Dublin 7
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT07116473 · EU 2024-513676-18-00 - 3. fázisTaking peopleAcoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Where
- Dublin 24, Dublin 7
- Életkor
- 18 év to 75 év
- People
- 587 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00